Description
NLG919 is an inhibitor of indoleamine-2,3-dioxygenase (IDO). This compound displays anticancer chemotherapeutic activity, prolonging survival rates in animal models of glioblastoma.
References
Vacchelli E, Aranda F, Eggermont A, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2014 Dec 15;3(10):e957994. PMID: 25941578.
Li M, Bolduc AR, Hoda MN, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. PMID: 25054064.